Efficacy and safety of sitagliptin for the treatment of diabetes mellitus complicated by chronic liver injury

Masahiro Asakawa, Hiroshi Mitsui, Momoko Akihisa, Tetsuo Sekine, Yoshihiro Niitsu, Arisa Kobayashi, Atsuko Miyake, Naoaki Hashimoto, Mitsunobu Kawamura, Yoshihiro Ogawa

研究成果: ジャーナルへの寄稿記事

10 引用 (Scopus)

抜粋

Aim: To investigate the efficacy and safety of a dipeptidyl peptidase-4 inhibitor, sitagliptin, for treating diabetes mellitus complicated by chronic liver injury. Methods: Sitagliptin was administered for 13.7 ± 10.1 months to 122 patients with DM complicated by chronic liver injury (including 19 patients with liver cirrhosis), and changes in hemoglobin A1c (HbA1c) and liver enzymes (transaminases, etc.) were evaluated. Results: HbA1c was reduced from 8.48 ± 1.43% to 7.87 ± 1.35% (P < 0.001). Among liver enzymes, alanine aminotransferase (ALT) levels improved from 75.1 ± 45.2 to 65.8 ± 35.8 IU/L (P = 0.012) and gamma-glut amyl-trans peptidase from 155.2 ± 161.1 to 133.2 ± 127.4 IU/L (P = 0.044). Among the causes of liver injury, non-alcoholic fatty liver disease and alcoholic liver disease both showed the reductions in HbA1c with no deterioration of liver enzymes. An analysis of 19 patients with liver cirrhosis also showed reductions in HbA1c with no deterioration of liver enzymes. Conclusion: It is suggested that sitagliptin can be administered effectively and safely to patients with diabetes mellitus complicated by chronic liver injury, including liver cirrhosis.

元の言語英語
記事番号346
ジャーナルSpringerPlus
4
発行部数1
DOI
出版物ステータス出版済み - 12 28 2015
外部発表Yes

All Science Journal Classification (ASJC) codes

  • General

フィンガープリント Efficacy and safety of sitagliptin for the treatment of diabetes mellitus complicated by chronic liver injury' の研究トピックを掘り下げます。これらはともに一意のフィンガープリントを構成します。

  • これを引用

    Asakawa, M., Mitsui, H., Akihisa, M., Sekine, T., Niitsu, Y., Kobayashi, A., Miyake, A., Hashimoto, N., Kawamura, M., & Ogawa, Y. (2015). Efficacy and safety of sitagliptin for the treatment of diabetes mellitus complicated by chronic liver injury. SpringerPlus, 4(1), [346]. https://doi.org/10.1186/s40064-015-1135-z